Envista (NYSE:NVST) Updates FY 2026 Earnings Guidance

Envista (NYSE:NVST) issued an update on its FY 2026 earnings guidance on Wednesday. The company provided EPS guidance of 1.500-1.550 for the period, compared to the consensus earnings per share estimate of 1.430. The company issued revenue guidance of -.

Analysts Set New Price Targets

NVST has been the subject of several research analyst reports. Mizuho set a $29.00 target price on shares of Envista in a research report on Thursday. Robert W. Baird set a $34.00 price target on Envista in a research note on Thursday. Weiss Ratings lowered Envista from a “hold (c)” rating to a “hold (c-)” rating in a report on Monday, May 11th. Morgan Stanley set a $23.00 price objective on Envista in a research note on Thursday. Finally, Citigroup initiated coverage on Envista in a research report on Wednesday, April 15th. They issued a “neutral” rating and a $29.00 target price for the company. Six analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. Based on data from MarketBeat, Envista currently has a consensus rating of “Hold” and an average price target of $29.31.

Envista Stock Performance

Shares of NYSE:NVST traded up $0.84 during trading on Friday, reaching $28.22. 4,051,710 shares of the company’s stock traded hands, compared to its average volume of 2,972,259. The stock has a market capitalization of $4.59 billion, a P/E ratio of 48.65, a price-to-earnings-growth ratio of 1.62 and a beta of 0.86. Envista has a 12 month low of $18.77 and a 12 month high of $30.42. The company has a 50 day moving average of $25.94 and a 200-day moving average of $26.01. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.44 and a quick ratio of 2.06.

Envista (NYSE:NVST) last issued its earnings results on Wednesday, August 5th. The company reported $0.41 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.34 by $0.07. Envista had a net margin of 3.33% and a return on equity of 7.87%. The firm had revenue of $730.50 million for the quarter, compared to analysts’ expectations of $716.11 million. During the same quarter last year, the company posted $0.26 earnings per share. Envista’s revenue was up 7.1% on a year-over-year basis. Envista has set its FY 2026 guidance at 1.500-1.550 EPS. On average, equities analysts expect that Envista will post 1.42 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Caitong International Asset Management Co. Ltd increased its position in Envista by 16,711.1% in the third quarter. Caitong International Asset Management Co. Ltd now owns 1,513 shares of the company’s stock worth $31,000 after buying an additional 1,504 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Envista by 73.1% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 2,248 shares of the company’s stock worth $44,000 after acquiring an additional 949 shares during the last quarter. UMB Bank n.a. grew its position in shares of Envista by 46.1% during the fourth quarter. UMB Bank n.a. now owns 2,017 shares of the company’s stock worth $44,000 after acquiring an additional 636 shares during the last quarter. EverSource Wealth Advisors LLC grew its position in shares of Envista by 378.0% during the second quarter. EverSource Wealth Advisors LLC now owns 2,414 shares of the company’s stock worth $47,000 after acquiring an additional 1,909 shares during the last quarter. Finally, Quarry LP acquired a new stake in shares of Envista in the 3rd quarter worth about $66,000.

About Envista

Envista Holdings Corporation is a global dental products company that develops, manufactures and markets a broad portfolio of dental consumables, equipment and technology solutions. Headquartered in Brea, California, Envista serves dental practitioners, specialists and laboratories in more than 150 countries. The company’s offerings span implant, orthodontic, endodontic and restorative product lines as well as digital imaging systems and practice management software.

Envista’s product brands include Nobel Biocare for dental implants and restorative solutions, Ormco for orthodontic appliances and treatment systems, Kerr for restorative and endodontic materials, KaVo for dental imaging and handpieces, and Vista for surgical drills and instruments.